*EMBARGOED All research presented at the ACG Annual Scientific Meeting is strictly embargoed until Monday, October 17, 2016 at 8:00 am EDT.
Poster 467 Significantly Improved Outcomes for U.S. Liver Transplant Candidates with HCV
Author Insight from Ju Dong Yang, MD, MSc, Mayo Clinic
What’s new here and important for clinicians?
In this work, we identified adult LT registrants between 2004 and 2015 from the UNOS/OPTN registry and found that HCV was the leading listing diagnosis between 2004 and 2014, but the number of HCV registrants (without HCC) dropped steeply after 2011, so that by 2015 it had become the third most common listing diagnosis after HCC and alcohol. We found that recent era (2011-2014) was associated with decreased probability of dropout due to deterioration or death in HCV (HR, 0.90; P=0.0003), and increased probability of delisting due to clinical improvement in HCV (HR, 3.4; P<0.0001) after adjusting for covariates. Recent era was associated with decreased risk of graft loss or death with a largest effect size seen in HCV recipients (HR, 0.76; P<0.0001).
What do patients need to know?
Indication for liver transplantation has recently changed rapidly in the United States. While the number of registrants with HCV has decreased, the pre- and post-liver transplant outcome has substantially improved in HCV patients.
Ju Dong Yang, MD, MSc, Mayo Clinic
Media Interview Requests:
To arrange an interview with any ACG experts or abstract authors, please contact Brian Davis of ACG via email at firstname.lastname@example.org or by phone at 301-263-9000.